Opioids are gaining prominence in the healthcare industry for treating chronic disease

 

Opioids have high degrees of abuse potential and must be closely monitored in patients receiving long haul treatment for chronic pain. Opioids are highly effective pain management systems when used appropriately but can be extremely addictive. There are currently 3 subgroup classifications of opioids used to treat pain. These include non-opioid analgesics; opioids; and mixed agonists or multitasking agents.

The growing prevalence of chronic diseases that cause pain such as for example cancer and arthritis is augmenting industry growth of Opioids.There have been 17 million new cases of cancer worldwide in 2018. The four most frequent cancers occurring worldwide are lung, female breast, bowel, and prostate cancer. This four take into account a lot more than four in ten of cancers diagnosed worldwide. Moreover, the increasing geriatric population along with the growing disposable income of the consumer is further projected to augment industry growth of opioids. Increasing the use of opioids for treatment, anesthesia, diarrhea suppression, cough suppression, and de-addiction can also be expected to operate a vehicle industry growth. On another hand, side-effects such as for example confusion, constipation, drowsiness, nausea, and euphoria associated with the use of opioids are projected to hinder industry size.

From the geographical point of view, North America is expected to get significant growth over the forecast period and this really is attributed to the strong presence of the healthcare industry in the region. In line with the National Health Expenditures, the U.S. health care spending increased 3.9 percent to reach $3.5 trillion, or $10,739 per person in 2017. Private medical insurance spending increased 4.2 percent to $1.2 trillion in 2017, which was slower than 6.2 percent growth in 2016.

Key Developments:

In August 2020, Trevena launched its first drug approval a week ago with intravenous opioid Olinvyk.In January 2020, Cumberland Pharmaceuticals Inc. a niche pharmaceutical company with a focus on hospital acute care announced the launch of Caldolor® (ibuprofen) Injection in a ready-to-use bag that could be administered without dilution for pain relief.

In July 2019, Reckitt Benckiser has agreed to pay up to $1.4 billion to eliminate the U.S. claims that its former pharmaceuticals business Indivior carried out an illegal scheme to improve sales of opioid addiction treatment.

In March 2020, Dr. Reddy's Laboratories announced first-to-market launch of Naloxone Hydrochloride injection in the US market.In August 2019, UO and OHSU enter into partnership on opioid research with $10M grant.